Ligand Pharmaceuticals Inc (LGND)
78.54
-0.44
(-0.56%)
USD |
NASDAQ |
Jun 26, 10:17
Ligand Pharmaceuticals SG&A Expense (Annual): 52.79M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 52.79M |
| December 31, 2022 | 70.06M |
| December 31, 2021 | 46.79M |
| December 31, 2020 | 60.01M |
| December 31, 2019 | 41.88M |
| December 31, 2018 | 37.73M |
| December 31, 2017 | 28.65M |
| December 31, 2016 | 27.65M |
| December 31, 2015 | 25.40M |
| December 31, 2014 | 22.57M |
| December 31, 2013 | 17.98M |
| December 31, 2012 | 15.78M |
| December 31, 2011 | 14.58M |
| December 31, 2010 | 12.83M |
| December 31, 2009 | 30.45M |
| Date | Value |
|---|---|
| December 31, 2008 | 23.78M |
| December 31, 2007 | 30.41M |
| December 31, 2006 | 43.91M |
| December 31, 2005 | 23.13M |
| December 31, 2004 | 76.51M |
| December 31, 2003 | 61.90M |
| December 31, 2002 | 41.82M |
| December 31, 2001 | 34.43M |
| December 31, 2000 | 34.11M |
| December 31, 1999 | 27.26M |
| December 31, 1998 | 16.60M |
| December 31, 1997 | 10.10M |
| December 31, 1996 | 10.20M |
| December 31, 1995 | 8.00M |
| December 31, 1994 | 7.00M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
41.88M
Minimum
2019
70.06M
Maximum
2022
54.31M
Average
52.79M
Median
2023
SG&A Expense (Annual) Benchmarks
| ANI Pharmaceuticals Inc | 161.70M |
| Annovis Bio Inc | 6.244M |
| United Therapeutics Corp | 477.10M |
| ADMA Biologics Inc | 59.02M |
| Blueprint Medicines Corp | 295.14M |